Huang Ziyue, Xia Haoming, Cui Yunfu, Yam Judy Wai Ping, Xu Yi
Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
J Clin Transl Hepatol. 2023 Feb 28;11(1):207-218. doi: 10.14218/JCTH.2022.00255. Epub 2022 Aug 31.
Hepatocellular carcinoma (HCC) is one of the most common and highly heterogeneous malignancies worldwide. Despite the rapid development of multidisciplinary treatment and personalized precision medicine strategies, the overall survival of HCC patients remains poor. The limited survival benefit may be attributed to difficulty in early diagnosis, the high recurrence rate and high tumor heterogeneity. Ferroptosis, a novel mode of cell death driven by iron-dependent lipid peroxidation, has been implicated in the development and therapeutic response of various tumors, including HCC. In this review, we discuss the regulatory network of ferroptosis, describe the crosstalk between ferroptosis and HCC-related signaling pathways, and elucidate the potential role of ferroptosis in various treatment modalities for HCC, such as systemic therapy, radiotherapy, immunotherapy, interventional therapy and nanotherapy, and applications in the diagnosis and prognosis of HCC, to provide a theoretical basis for the diagnosis and treatment of HCC to effectively improve the survival of HCC patients.
肝细胞癌（HCC）是全球最常见且高度异质性的恶性肿瘤之一。尽管多学科治疗和个性化精准医学策略迅速发展，但HCC患者的总体生存率仍然很低。生存获益有限可能归因于早期诊断困难、高复发率和高肿瘤异质性。铁死亡是一种由铁依赖性脂质过氧化驱动的新型细胞死亡模式，已被证明与包括HCC在内的各种肿瘤的发生发展及治疗反应有关。在这篇综述中，我们讨论了铁死亡的调控网络，描述了铁死亡与HCC相关信号通路之间的相互作用，并阐明了铁死亡在HCC的各种治疗方式（如全身治疗、放疗、免疫治疗、介入治疗和纳米治疗）中的潜在作用，以及在HCC诊断和预后中的应用，为HCC的诊断和治疗提供理论依据，以有效提高HCC患者的生存率。
